Cargando…
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
Despite the wide use of immune checkpoint inhibition for the treatment of melanoma, the mechanisms leading to long-term stable disease are incompletely understood. Patients with metastatic melanoma who had received ipilimumab alone or ipilimumab plus nivolumab 2+years prior and attained at least 6 m...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168111/ https://www.ncbi.nlm.nih.gov/pubmed/37115942 http://dx.doi.org/10.1097/CJI.0000000000000470 |
_version_ | 1785038804752531456 |
---|---|
author | Buchbinder, Elizabeth I. Pfaff, Kathleen L. Turner, Madison M. Manos, Michael Ouyang, Olivia Ott, Patrick A. Giobbie-Hurder, Anita Rodig, Scott J. Hodi, F. Stephen |
author_facet | Buchbinder, Elizabeth I. Pfaff, Kathleen L. Turner, Madison M. Manos, Michael Ouyang, Olivia Ott, Patrick A. Giobbie-Hurder, Anita Rodig, Scott J. Hodi, F. Stephen |
author_sort | Buchbinder, Elizabeth I. |
collection | PubMed |
description | Despite the wide use of immune checkpoint inhibition for the treatment of melanoma, the mechanisms leading to long-term stable disease are incompletely understood. Patients with metastatic melanoma who had received ipilimumab alone or ipilimumab plus nivolumab 2+years prior and attained at least 6 months of stable disease were identified. Positron emission tomography/computed tomography (PET/CT) was performed. Pretreatment and posttreatment biopsies of areas of stable disease were assessed for tumor, fibrosis, and inflammation. Seven patients underwent PET/CT and tissue biopsy. Fluorodeoxyglucose avid lesions on PET/CT ranged from no activity to an SUV of 22. In 6 patients, the residual stable lesions were composed of necrosis and fibrosis with a prominent pigment containing macrophages and no residual melanoma. In 1 patient, a nodal lesion demonstrated melanoma with active inflammation. In most patients with durable stable disease after treatment with ipilimumab or ipilimumab/nivolumab, residual lesions demonstrated predominantly necrosis and fibrosis consistent with resolving lesions. The presence of melanophages in these samples may suggest ongoing immune surveillance. One patient did demonstrate residual melanoma, indicating the need for ongoing monitoring of this patient population. |
format | Online Article Text |
id | pubmed-10168111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-101681112023-05-10 Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy Buchbinder, Elizabeth I. Pfaff, Kathleen L. Turner, Madison M. Manos, Michael Ouyang, Olivia Ott, Patrick A. Giobbie-Hurder, Anita Rodig, Scott J. Hodi, F. Stephen J Immunother Clinical Studies Despite the wide use of immune checkpoint inhibition for the treatment of melanoma, the mechanisms leading to long-term stable disease are incompletely understood. Patients with metastatic melanoma who had received ipilimumab alone or ipilimumab plus nivolumab 2+years prior and attained at least 6 months of stable disease were identified. Positron emission tomography/computed tomography (PET/CT) was performed. Pretreatment and posttreatment biopsies of areas of stable disease were assessed for tumor, fibrosis, and inflammation. Seven patients underwent PET/CT and tissue biopsy. Fluorodeoxyglucose avid lesions on PET/CT ranged from no activity to an SUV of 22. In 6 patients, the residual stable lesions were composed of necrosis and fibrosis with a prominent pigment containing macrophages and no residual melanoma. In 1 patient, a nodal lesion demonstrated melanoma with active inflammation. In most patients with durable stable disease after treatment with ipilimumab or ipilimumab/nivolumab, residual lesions demonstrated predominantly necrosis and fibrosis consistent with resolving lesions. The presence of melanophages in these samples may suggest ongoing immune surveillance. One patient did demonstrate residual melanoma, indicating the need for ongoing monitoring of this patient population. Lippincott Williams & Wilkins 2023-06 2023-05-01 /pmc/articles/PMC10168111/ /pubmed/37115942 http://dx.doi.org/10.1097/CJI.0000000000000470 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Clinical Studies Buchbinder, Elizabeth I. Pfaff, Kathleen L. Turner, Madison M. Manos, Michael Ouyang, Olivia Ott, Patrick A. Giobbie-Hurder, Anita Rodig, Scott J. Hodi, F. Stephen Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy |
title | Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy |
title_full | Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy |
title_fullStr | Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy |
title_full_unstemmed | Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy |
title_short | Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy |
title_sort | brief communication on pathologic assessment of persistent stable metastatic lesions in patients treated with anti-ctla-4 or anti-ctla-4 + anti-pd-1 therapy |
topic | Clinical Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168111/ https://www.ncbi.nlm.nih.gov/pubmed/37115942 http://dx.doi.org/10.1097/CJI.0000000000000470 |
work_keys_str_mv | AT buchbinderelizabethi briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy AT pfaffkathleenl briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy AT turnermadisonm briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy AT manosmichael briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy AT ouyangolivia briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy AT ottpatricka briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy AT giobbiehurderanita briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy AT rodigscottj briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy AT hodifstephen briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy |